Publications in collaboration with researchers from University of Pavia (14)

2025

  1. Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

    Schizophrenia Bulletin Open, Vol. 6, Núm. 1

  2. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  3. Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

    Schizophrenia Bulletin Open, Vol. 6, Núm. 1

  4. Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  5. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  6. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

    Schizophrenia, Vol. 11, Núm. 1

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

2021

  1. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

2019

  1. Basic self-disturbances related to reduced anterior cingulate volume in subjects at ultra-high risk for psychosis

    Frontiers in Psychiatry, Vol. 10, Núm. MAY

2016

  1. An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications

    Comprehensive Psychiatry, Vol. 66, pp. 39-45

  2. Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification

    JAMA Psychiatry, Vol. 73, Núm. 2, pp. 113-120

  3. Neurobiological models of self-disorders in early schizophrenia

    Schizophrenia Bulletin, Vol. 42, Núm. 4, pp. 874-880

  4. Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis

    Psychiatry Research, Vol. 238, pp. 270-276